-
HIV and the Antiretroviral Therapy Capsid Inhibitor Lenacapavir
David Orchard-Webb
January 07, 2025
HIV is a major worldwide health issue, producing substantial morbidity and mortality.HIV targets the immune system, primarily CD4+ T cells, depleting them and making the body susceptible to opportunistic infections and malignancies.
-
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Opt
drugs
July 08, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the FDA seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor.
-
Gilead seeks US approval for long-acting HIV drug lenacapavir
pharmatimes
July 01, 2021
Gilead has filed its investigational long-acting HIV drug lenacapavir with the US Food and Drug Administration (FDA), seeking approval in patients with multi-drug resistant infection.
-
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations
expresspharma
March 16, 2021
Gilead Sciences and Merck, known as MSD outside the US and Canada, announced that they have entered into an agreement to co-develop and co-commercialise long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir ...